Supervisor Database Search

Guidance for ICAT Supervisors

The ICAT Supervisor list is reviewed annually by the partner universities and updated online in March/April each year.

You can read about the ICAT supervisor selection process and eligibility criteria below:

Terms of reference/guide to supervising ICAT Fellows.

You can read the terms of reference for supervisors actively supervising ICAT Fellows below:

Supervisor Database

Search for supervisors below. You can filter your search using the options and select multiple fields by holding CTRL (Cmd on Mac) + clicking multiple options in a list.

Full NameProfessor Timothy O'Brien

Medicine

University of Galway

Webpage:remedi.ie

Email hidden; Javascript is required.

Research Fields
  • cell and developmental biology/regenerative medicine
  • physiology and non-communicable disease
  • clinical trials
Postgrad Medical Specialties
  • Medicine
  • Emergency Medicine
  • General Practice
  • Public Health
Medical Subspecialties
  • Cardiology
  • Endocrinology
  • Immunology
  • Nephrology
  • Neurology
  • Vascular Medicine
My Work

My research interests include the translation of basic research findings in stem cell biology to regenerative approaches to peripheral vascular disease and diabetic complications in partnership with industry and the health service. I have an active research group at REMEDI NUI Galway investigating the use of mesenchymal stromal cells and endothelial progenitor cells in vascular complications of diabetes mellitus.

I am Director of the GMP cell manufacturing facility at NUI Galway and have been a PI on gene therapy and cell therapy clinical trials in Galway. In addition to a laboratory-based programme, my research brings together the Galway HRB Clinical Research Facility, the Galway Blood and Tissue Establishment and the Centre for Cell Manufacturing Ireland for translational research in stem cells and gene therapy.

I am coordinator of 2 current EU funded projects; EU FP7 REDDSTAR which is developing and testing a novel stromal cell therapy to treat complications of diabetes mellitus (www.reddstar.eu) and the EU H2020 NEPHSTROM (www.nephstrom.eu), which will clinically validate a novel stromal cell therapy for the stabilization of progressive diabetic kidney disease.

Scroll to Top